Literature DB >> 12684767

Overexpression of IGBFB2 is a marker for malignant transformation in prostate epithelium.

Elin Richardsen1, Tanja Ukkonen, Tone Bjørnsen, Elin Mortensen, Lars Egevad, Christer Busch.   

Abstract

Insulin-like growth factor binding protein 2 (IGFBP2) has been shown to be overexpressed in prostatic intraepithelial neoplasia (PIN) and invasive cancer and the serum level to parallel that of prostate-specific antigen (PSA) in prostate cancer. A combination of cDNA and tissue microarray results recently demonstrated overexpression of IGFBP2 in hormone refractory prostate cancer, indicating that the IGF system may be part of a key growth regulatory pathway in prostate cancer. The present study reexamines the immunohistochemical expression of IGFBP2 and its relationship to grade in tissue from 193 radical prostatectomy specimens from patients with localized prostate adenocarcinoma. We found a significant overexpression of IGFBP2 in all instances of PIN and in more than 90% of cancers regardless of the grade. An intense overexpression was noted in the neuroendocrine cells in normal glands as well as in cancer. The IGFBP2 expression was also analyzed in 18 cases of biopsy diagnosed prostate cancer. In all these cases, the glands interpreted as invasive cancer in hematoxylin-eosin stained sections overexpressed IGFBP2, without a significant correlation to grade. We conclude that overexpression of IGFBP2 is a powerful marker for malignant transformation in the prostate epithelium and suggest that optimized immunohistochemical detection of IGFBP2 expression may be an adjunct tool in the diagnosis of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12684767     DOI: 10.1007/s00428-003-0786-2

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  32 in total

Review 1.  Cellular features distinguishing benign and malignant phenotypes in prostatic biopsies.

Authors:  C S Foster
Journal:  Hum Pathol       Date:  2000-12       Impact factor: 3.466

Review 2.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

Review 3.  Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions.

Authors:  S Rajaram; D J Baylink; S Mohan
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

4.  Identification of differentially expressed genes in human prostate cancer using subtraction and microarray.

Authors:  J Xu; J A Stolk; X Zhang; S J Silva; R L Houghton; M Matsumura; T S Vedvick; K B Leslie; R Badaro; S G Reed
Journal:  Cancer Res       Date:  2000-03-15       Impact factor: 12.701

5.  Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Authors:  P Stattin; A Bylund; S Rinaldi; C Biessy; H Déchaud; U H Stenman; L Egevad; E Riboli; G Hallmans; R Kaaks
Journal:  J Natl Cancer Inst       Date:  2000-12-06       Impact factor: 13.506

6.  Hormone therapy failure in human prostate cancer: analysis by complementary DNA and tissue microarrays.

Authors:  L Bubendorf; M Kolmer; J Kononen; P Koivisto; S Mousses; Y Chen; E Mahlamäki; P Schraml; H Moch; N Willi; A G Elkahloun; T G Pretlow; T C Gasser; M J Mihatsch; G Sauter; O P Kallioniemi
Journal:  J Natl Cancer Inst       Date:  1999-10-20       Impact factor: 13.506

7.  IGFBP-2 expression in a human cell line is associated with increased IGFBP-3 proteolysis, decreased IGFBP-1 expression and increased tumorigenicity.

Authors:  M Menouny; M Binoux; S Babajko
Journal:  Int J Cancer       Date:  1998-09-11       Impact factor: 7.396

8.  Immunohistochemical localization of insulin-like growth factor binding proteins 2 and 3 in prostate tissue: clinical correlations.

Authors:  J B Thrasher; M K Tennant; P A Twomey; K L Hansberry; J N Wettlaufer; S R Plymate
Journal:  J Urol       Date:  1996-03       Impact factor: 7.450

9.  Insulin-like growth factor-binding protein-2 and -3 expression in benign human prostate epithelium, prostate intraepithelial neoplasia, and adenocarcinoma of the prostate.

Authors:  M K Tennant; J B Thrasher; P A Twomey; R S Birnbaum; S R Plymate
Journal:  J Clin Endocrinol Metab       Date:  1996-01       Impact factor: 5.958

10.  Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer.

Authors:  P Cornford; J Evans; A Dodson; K Parsons; A Woolfenden; J Neoptolemos; C S Foster
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

View more
  14 in total

1.  Differential expression of IGF components and insulin receptor isoforms in human seminoma versus normal testicular tissue.

Authors:  Tanja Pascale Neuvians; Isabella Gashaw; Andrea Hasenfus; Axel Hacherhäcker; Elke Winterhager; Rainer Grobholz
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

2.  Acquired loss of renal nuclease activity is restricted to DNaseI and is an organ-selective feature in murine lupus nephritis.

Authors:  Natalya Seredkina; Ole P Rekvig
Journal:  Am J Pathol       Date:  2011-06-30       Impact factor: 4.307

Review 3.  Do all lung adenocarcinomas follow a stepwise progression?

Authors:  Yasushi Yatabe; Alain C Borczuk; Charles A Powell
Journal:  Lung Cancer       Date:  2011-06-25       Impact factor: 5.705

4.  Significant expression of IGFBP2 in breast cancer compared with benign lesions.

Authors:  L-T Busund; E Richardsen; R Busund; T Ukkonen; T Bjørnsen; C Busch; H Stalsberg
Journal:  J Clin Pathol       Date:  2005-04       Impact factor: 3.411

5.  Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables.

Authors:  Yi-Hong Zhou; Kenneth R Hess; Longjian Liu; Mark E Linskey; W K Alfred Yung
Journal:  Neuro Oncol       Date:  2005-10       Impact factor: 12.300

6.  Expression of insulin-like growth factor binding protein-2 in gastric carcinoma and its relationship with cell proliferation.

Authors:  Liang-Hui Shi; Xiao-Qun Zhu; Guo-Hai Zhao; Ya-Bin Xia; Yi-Sheng Zhang
Journal:  World J Gastroenterol       Date:  2006-10-21       Impact factor: 5.742

7.  IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Authors:  Oren J Becher; Katia M Peterson; Soumen Khatua; Maria R Santi; Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

8.  Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20.

Authors:  Gianluca Marucci; Luca Morandi; Elisabetta Magrini; Anna Farnedi; Enrico Franceschi; Rossella Miglio; Daniela Calò; Annalisa Pession; Maria P Foschini; Vincenzo Eusebi
Journal:  Virchows Arch       Date:  2008-10-25       Impact factor: 4.064

9.  Tumor suppressor menin regulates expression of insulin-like growth factor binding protein 2.

Authors:  Ping La; Robert W Schnepp; Clark D Petersen; Albert C Silva; Xianxin Hua
Journal:  Endocrinology       Date:  2004-03-24       Impact factor: 4.736

10.  Expression of IGFBP2 in gastric carcinoma and relationship with clinicopathologic parameters and cell proliferation.

Authors:  Lihua Zhang; Wenbin Huang; Jieyu Chen; Xiaojun Zhou; Zhenfeng Lu; Hangbo Zhou
Journal:  Dig Dis Sci       Date:  2006-12-15       Impact factor: 3.487

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.